- Thinly traded nano cap Rock Creek Pharmaceuticals (OTC:RCPI-OLD +15.1%) jumps on a 5x surge in volume in response to its announcement of positive results of a 10-subject human proof-of-principle study of its lead product candidate, anatabine citrate. Results showed that a single oral dose can significantly inhibit the activation of inflammatory proteins in human white blood cells.
- A Phase 1 trial is being planned in the UK.
- Anatabine citrate is a small molecule cholinergic (refers to the neurotransmitter acetylcholine) agonist which exhibits anti-inflammatory pharmacological characteristics. Its mechanism of action is different than other anti-inflammatory drugs such as biologics and steroids.
Rock Creek Pharma announces positive study results for lead product candidate; shares up 15%
Recommended For You
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
RCPI-OLD | - | - |
Rock Creek Pharmaceuticals, Inc. |